

## **Sedative Hypnotics**

Member Information									
1. La:	st Name:			2. First Name:					
3. Tri	llium ID #:		2. First Name: 4. Date of Birth:				5. Gender:		
Prescrib	er Information								
1. Pro	Prescriber Name:								
3. Re	questor Name (	Nurse/Office Staff):							
4. Ma	ailing Address: _				City:		State:	Zip:	
3. Ph	one #:		E>	kt	Fax #:				
Drug In	formation								
1. Dru	g Name:		2. Streng	gth:		3. Quantity I	Per 30 Days:	:	
4. Leng	gth of Therapy (i	in Days): □ up to 30	□ 60 □ 90 □ 1	120 🗆 180	) □ Other:	(Max the	erapy length	is 180 days)	
Clinical	Information								
For No	n-Preferred Dr	ugs							
1. Fa	•	ed drug(s). List prefe	_						
	a. Was the failure due to an allergic reaction?   Yes  No								
	<ul><li>b. Was the failure due to a drug-to-drug interaction? ☐ Yes ☐ No</li></ul>								
P	Please describe reaction:								
2. Pro	Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:								
	Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s).								
Ple	Please provide clinical information:								
	Age specific indications. Please give patient age and explain:								
	Unique clinical indication supported by FDA approval or peer reviewed literature.  Please explain and provide a general reference:								
6. Un	. Unacceptable clinical risk associated with therapeutic change. Please explain:								
Criteria for Quantity Limits: Exceeding Quantity of 15 per 30 days (check all that apply)									
	. Does member have a diagnosis of chronic primary insomnia lasting one month or longer? ☐ <b>Yes</b> ☐ <b>No</b>								
8. Ha	Has member received information on good sleep hygiene and had a documented trial (at least 3 weeks) of non-								
-	pharmacological therapies (ex. stimulus control, sleep restriction, sleep hygiene measures and relaxation therapy)?								
	□ Yes □ No								
	Does member have diagnosis of chronic secondary or co-morbid insomnia lasting one month or longer and has								
	been evaluated for and is being actively treated for one of the below conditions?   Yes  No Please check appropriate condition:								
		sychiatric illness asso	ociated with inco	omnia					
	,	•			ronic nain ac	scociated with	cancar infla	ammatary	
	☐ b. underlying medical illness associated with insomnia (ex. chronic pain associated with cancer, inflammatory arthritis etc.)								
		r such as restless le	gs syndrome, sl	leep-relate	ed breathing	disorder, sleep	related mo	ovement	
	disorder, or circadian rhythm disorder								
	0. Is member being discontinued from a sedative hypnotic and tapering is required to prevent symptoms of								
	withdrawal? ☐ <b>Yes</b> ☐ <b>No</b> Is the member being actively assessed for a diagnosis of chronic primary or secondary/co-morbid insomnia?								
Yes □ No (Do not check "yes" if answer to #7 above is "yes")							пппа:		
	1 00 L 140 (DO III	or official yes it alls		Jio yes )					
<b>C</b> :						Dat			
Signa	ture of Prescribe	er:				_ Date:			

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.